TRDA — Entrada Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1689375 ·
Last close
$6.70
Market Cap
$260.10M
52W High
$16.45
52W Low
$5.63
ADV30
517,540
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 875,000 | — | -42,303,000 | -39,717,000 | 335,518,000 | 76,444,000 | 64,664,000 |
| Dec 2025 | 1,299,000 | — | -42,208,000 | -39,164,000 | 377,378,000 | 90,394,000 | 71,245,000 |
| Sep 2025 | 1,614,000 | — | -47,051,000 | -44,134,000 | 412,898,000 | 93,286,000 | 72,182,000 |
| Jun 2025 | 1,950,000 | — | -46,849,000 | -43,103,000 | 448,783,000 | 72,482,000 | 69,278,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-128,512,000
Investing CF
$116,808,000
Financing CF
$887,000
CapEx
$-2,693,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.46
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-273,094,000
Inventory
—
Receivables
$1,177,000
ST Investments
$205,304,000
EBIT TTM
$-157,898,000
Pretax Income TTM
$-142,826,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,738,000
EBITDA
$-172,556,000
Free Cash Flow
$-75,381,376
Enterprise Value
$36,315,772
Total Cash
$254,859,008
Total Debt
$49,750,000
Shares Out
38,820,616
Trailing EPS
$-3.99
Book Value
$8.50
ROE
-48.3%
ROA
-26.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 25,421,000 | -157,898,000 | -143,750,000 | 377,378,000 | 71,245,000 | — | -128,512,000 |
| Dec 2024 | 210,782,000 | 47,011,000 | 65,626,000 | 526,321,000 | 97,643,000 | — | -41,557,000 |
| Dec 2023 | 129,013,000 | -3,162,000 | -6,685,000 | 469,192,000 | 226,832,000 | — | 139,803,000 |
| Dec 2022 | 0 | -97,248,000 | -94,616,000 | 252,056,000 | 39,502,000 | — | -93,786,000 |
TTM Snapshot
Revenues TTM
$63,305,000
NetIncome TTM
$-18,138,000
OpCashFlow TTM
$0
Assets (Latest)
$526,321,000
Forward EPS
$-3.41
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALXO | ALX ONCOLOGY HOLDINGS INC | $259.71M | $1.93 | — |
| FHTX | Foghorn Therapeutics Inc. | $256.58M | $4.37 | — |
| RLFTY | MindMaze Therapeutics Holding SA | $264.43M | $1.73 | — |
| PRLD | Prelude Therapeutics Inc | $265.51M | $4.09 | — |
| NVCT | Nuvectis Pharma, Inc. | $267.91M | $10.10 | — |
News headlines (Yahoo Finance, 1h cache)
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
2026-05-09 06:07 · Yahoo
Entrada’s stock drops as DMD drug’s efficacy falls short
2026-05-08 10:39 · Yahoo
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?
2026-05-07 20:04 · Yahoo
Sector Update: Health Care Stocks Softer Late Afternoon
2026-05-07 19:44 · Yahoo
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 12:50 · Yahoo
Entrada shares dive as Duchenne results disappoint
2026-05-07 11:14 · Yahoo
Entrada Therapeutics Reports First Quarter 2026 Financial Results
2026-05-07 11:10 · Yahoo
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
2026-05-07 11:00 · Yahoo
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
2026-05-06 20:30 · Yahoo
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
2026-05-05 13:12 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-05-21 16:31:31 | 2026-05-20 | Zeiher Bernhardt G | Dir | P - Purchase | 5.86 | 5000 | 29316 |